Skip to main content
. 2016 Nov 10;17(11):1876. doi: 10.3390/ijms17111876

Table 2.

Distribution of the mutation in IDH1 and MGMT promoter methylation among the patients according to their histopathological diagnosis (WHO II, III, IV). OS, Overall Survival.

Astrocytoma II (n = 57) (Median OS, Month) Astrocytoma III (n = 13) (Median OS, Month) Glioblastoma (n = 13) (Median OS, Month)
MGMT MGMT+ MGMT MGMT+ MGMT MGMT+
IDH1 pR132H 33 (n = 11) 47 (n = 24) 28 (n = 5) 47 (n = 7) 22 (n = 2) 22.5 (n = 6)
IDH1 WT 21 (n = 11) 19 (n = 11) 14 (n = 1) 0 7.5 (n = 4) 2 (n = 1)